Stay updated with breaking news from Zai Lab Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.
Osaka, Japan and Waltham, Massachusetts, April 30, 2024 - ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. today announced that on April 29, 2024 , ONO and Deciphera entered...
Zai Lab Ltd.'s (ZLAB) partner Novocure Ltd. (NVCR) announced on Wednesday that its phase 3 clinical trial in Tumor Treating Fields therapy for patients with 1-10 brain metastases from non-small cell lung cancer or NSCLC, has met its primary endpoint by demonstrating significant improvement in intracranial progression.
Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Strategic Progress and Financial Highlights Reflect Company's Growth Trajectory